Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Corcept Therapeutics (CORT) EPS (Weighted Average and Diluted) (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed EPS (Weighted Average and Diluted) for 11 consecutive years, with -$0.3 as the latest value for Q1 2026.

  • For Q1 2026, EPS (Weighted Average and Diluted) fell 276.47% year-over-year to -$0.3; the TTM value through Mar 2026 reached $0.35, down 69.57%, while the annual FY2025 figure was $0.82, 33.33% down from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.3 in Q1 2026 for Corcept Therapeutics, down from $0.2 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.41 in Q3 2024 and bottomed at -$0.3 in Q1 2026.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.21, with a median of $0.25 recorded in 2023.
  • Year-over-year, EPS (Weighted Average and Diluted) soared 100.0% in 2023 and then plummeted 276.47% in 2026.
  • Corcept Therapeutics' EPS (Weighted Average and Diluted) stood at $0.14 in 2022, then skyrocketed by 100.0% to $0.28 in 2023, then dropped by 10.71% to $0.25 in 2024, then dropped by 20.0% to $0.2 in 2025, then plummeted by 250.0% to -$0.3 in 2026.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.3, $0.2, and $0.16 for Q1 2026, Q4 2025, and Q3 2025 respectively.